Literature DB >> 9482440

Frequency of inherited bleeding disorders in women with menorrhagia.

R A Kadir1, D L Economides, C A Sabin, D Owens, C A Lee.   

Abstract

BACKGROUND: Although menorrhagia is a common gynaecological symptom, a specific cause is identified in less than 50% of affected women. We investigated the frequency of inherited bleeding disorders in women with menorrhagia.
METHODS: Women referred for investigation of menorrhagia whose pelvis was normal on clinical examination and who had an estimated menstrual blood loss of more than 80 mL were studied. A detailed menstrual history and history about other bleeding symptoms was taken. The activated partial thromboplastin time, factor VIII activity, von-Willebrand-factor antigen and activity, and factor XI (FXI) were measured in all patients; further tests were done when results were at or outside the limits of the assays.
FINDINGS: 150 women were screened. An inherited bleeding disorder was diagnosed in 26 (17%) patients: the disorders were von Willebrand's disease of mild (15) or moderate severity (three), mild FXI deficiency (four), mild von Willebrand's disease and FXI deficiency (one), combined von Willebrand's disease, FXI deficiency, and factor X deficiency (one), carriage of haemophilia-A gene (one), and platelet dysfunction (one). The frequency of von Willebrand's disease and FXI deficiency were 13% (95% CI 7.9-18.8%) and 4% (1.5-8.5%), respectively. Menorrhagia since menarche was noted in 11 (8.9%) of 123 women without a bleeding disorder compared with 13 (65%) of 20 women with von Willebrand's disease (p=0.001) and four (66.7%) of six women with FXI deficiency (p<0.001).
INTERPRETATION: Inherited bleeding disorders are found in a substantial proportion of women with menorrhagia and a normal pelvis examination. We suggest that such patients should be investigated for these disorders-especially von Willebrand's disease-before invasive procedures are done.

Entities:  

Mesh:

Year:  1998        PMID: 9482440     DOI: 10.1016/S0140-6736(97)08248-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  41 in total

Review 1.  Fortnightly review. Medical management of menorrhagia.

Authors:  A Prentice
Journal:  BMJ       Date:  1999-11-20

2.  Menorrhagia. Underlying bleeding disorders need to be ruled out.

Authors:  K Robinson; P Giangrande
Journal:  BMJ       Date:  2001-03-24

Review 3.  The levonorgestrel-releasing intrauterine system in heavy menstrual bleeding: a benefit-risk review.

Authors:  Andrew M Kaunitz; Pirjo Inki
Journal:  Drugs       Date:  2012-01-22       Impact factor: 9.546

4.  Platelet dysfunction and other hemostatic disorders in women with menorrhagia: the utility of whole blood lumi-aggregometer.

Authors:  O Meltem Akay; Fezan Mutlu; Zafer Gulbas
Journal:  Intern Emerg Med       Date:  2008-02-09       Impact factor: 3.397

5.  Acute uterine bleeding unrelated to pregnancy: a Southern California Permanente Medical Group practice guideline.

Authors:  Malcolm G Munro
Journal:  Perm J       Date:  2013

Review 6.  Hematologic complications of pregnancy.

Authors:  Danielle M Townsley
Journal:  Semin Hematol       Date:  2013-07       Impact factor: 3.851

7.  The diagnosis and treatment of von Willebrand disease in children.

Authors:  Robert J Klaassen; Jacqueline M Halton
Journal:  Paediatr Child Health       Date:  2002-04       Impact factor: 2.253

8.  Medical management of menorrhagia.

Authors:  A Prentice
Journal:  West J Med       Date:  2000-04

9.  Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report.

Authors:  E Berntorp; B Fuchs; M Makris; R Montgomery; V Flood; J S O'Donnell; A B Federici; D Lillicrap; P James; U Budde; M Morfini; P Petrini; S Austin; C Kannicht; V Jiménez-Yuste; C Lee
Journal:  Haemophilia       Date:  2013-03       Impact factor: 4.287

10.  Evaluation of bleeding disorders in women with menorrhagia: a survey of obstetrician-gynecologists.

Authors:  Vanessa R Byams; Britta L Anderson; Althea M Grant; Hani Atrash; Jay Schulkin
Journal:  Am J Obstet Gynecol       Date:  2012-07-16       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.